Get to know our clinical trials
A Phase I/IIa clinical trial of an infusion of autologous peripheral blood T cells that have been expanded and transduced using Sleeping Beauty technology to express a chimeric antigen receptor with anti-CD19 specificity.
THE TRANSPOCALL19 STUDY IS A CLINICAL TRIAL FOR PEOPLE WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHO HAVE RECEIVED STANDARD TREATMENTS BUT STILL REQUIRE FURTHER TREATMENT FOR THEIR DISEASE.
Technical Summary
- A SINGLE-CENTER PHASE I/IIA STUDY OF THE INFUSION OF AUTOLOGOUS PERIPHERAL BLOOD T CELLS THAT HAVE BEEN EXPANDED AND GENETICALLY MODIFIED USING SLEEPING BEAUTY TRANSPOSONS TO EXPRESS A CHIMERIC ANTIGEN RECEPTOR WITH ANTI- -CD19 SPECIFICITY, CONJUGATED WITH THE 4-1BB COSTIMULATORY REGION AND THE CD3Z AND HUEGFRT SIGNAL TRANSDUCTION REGIONS (TRANSPOCART19) IN PATIENTS WITH TREATMENT-RESISTANT OR REFRACTORY CD19-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA.
- Code EudraCT: 2025-522673-11-00
- Protocol number: TranspoCALL19
- Promoter: Clinica Universidad de Navarra
- Molecule/Drug: TranspoCART19
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.